PDF-EASL Recommendations on Treatment of Hepatitis C 2015

JULY 2015 SUMMARY Contents 1 Diagnosis of acute and chronic hepatitis C 2 Screening for chronic hepatitis C 3 Goals and endpoints of HCV therapy 4 Pretherapeutic assessment 5 Indications for t. Dr. Joanna Eveland, MS, MD. Clinical Chief for Special Populations, MNHC. O. bjectives. Understand recommendations for age cohort and risk based screening for Hepatitis C. Review strategies for health promotion and optimizing treatment readiness for HCV infected homeless individuals. Gottfried . Hirnschall. Background . HCV infection significant cause of morbidity and mortality:. 130–150 million persons with chronic HCV infection. 350,000–500,000 annual deaths. Rapidly changing therapeutic environment. Strategies To Identify and Advance PWID HCV Patient Care. Linkage to C Care Program. . Imtiaz Alam, M.D.. Medical Director, Austin Hepatitis Center. Medical Director, . HepCare. Specialty Pharmacy. IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Hepatitis B Virus Disease. Slide Set. 2. May 2015. www.aidsetc.org. These slides were developed using recommendations published in July 2013. The intended audience is clinicians involved in the care of patients with HIV. Certain sections have been updated to reflect changes in the published guidelines.. w. ho . i. nject . d. rugs (PWID) in India: . High burden but limited access to care. . Shruti H. Mehta, PhD MPH. Professor, Johns Hopkins Bloomberg School of Public Health. Department of Epidemiology. IAPAC African Regional Capacity-Building Hub. Based in Johannesburg, South Africa. Mission: Strengthen clinician capacity to deliver HIV, HBV, and HCV treatment . Partners include:. . Supported through an educational grant from: . Rachel Stallings, MPH. March 4, 2020. Hepatitis . Hepatitis = inflammation of the liver. Can be self-limiting or progress to fibrosis (scarring), cirrhosis, or liver cancer. . Causes:. Most commonly caused by a virus, there are 5: A, B, C, D & E. Oluwatoyin ( . Toyin. ) Adeyemi, MD. Director, CORE Viral hepatitis Clinic. Senior director for HIV services, Cook County Health . Triple Threat 11: HIV, HCV & . Opiods. Dusable. Museum , June 25, 2019. About these slides. These slides give a comprehensive overview of the EASL clinical practice guidelines on . the management of hepatitis E infection. The guidelines were first presented at the International Liver Congress 2018 and will be published soon in . HEPAMAP: HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS EASL EUROPEAN ASSOCIATION FOR THE STUDY OF April 10. –14. , 2019. Vienna, Austria. Disclaimer. These non-promotional slides are intended to be used as educational material only in response to an unsolicited question or request. The double-dagger (. Kristen M. Marks, MD. Assistant Professor. Weill Cornell Medical College . New York, New York. Financial Relationships With Commercial Entities. Dr Marks was awarded research grants, paid to her institution, from Bristol-Myers Squibb, Gilead Sciences, . Navigating Hepatitis C: . What Patients Need to Know . avigating. Hepatitis C: . What Patients Need to Know. Need to Know. HCV Screening. Bruce Burkett. Executive Director. HepC Alliance. Persons who have ever injected illegal drugs, including those who injected only once many years ago.